| Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study A Necchi, A Anichini, D Raggi, A Briganti, S Massa, R Lucianò, ... Journal of Clinical Oncology 36 (34), 3353-3360, 2018 | 663 | 2018 |
| Structure-based classification predicts drug response in EGFR-mutant NSCLC JP Robichaux, X Le, RSK Vijayan, JK Hicks, S Heeke, YY Elamin, HY Lin, ... Nature 597 (7878), 732-737, 2021 | 316 | 2021 |
| Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies A Necchi, D Raggi, A Gallina, R Madison, M Colecchia, R Luciano, ... European urology 77 (4), 439-446, 2020 | 286 | 2020 |
| Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC JW Riess, DR Gandara, GM Frampton, R Madison, N Peled, JA Bufill, ... Journal of Thoracic Oncology 13 (10), 1560-1568, 2018 | 241 | 2018 |
| Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms H Tukachinsky, RW Madison, JH Chung, OV Gjoerup, EA Severson, ... Clinical Cancer Research 27 (11), 3094-3105, 2021 | 153 | 2021 |
| Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors AB Schrock, VW Zhu, WS Hsieh, R Madison, B Creelan, J Silberberg, ... Journal of Thoracic Oncology 13 (9), 1312-1323, 2018 | 142 | 2018 |
| Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma C Ang, SJ Klempner, SM Ali, R Madison, JS Ross, EA Severson, ... Oncotarget 10 (40), 4018, 2019 | 140 | 2019 |
| Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study ZR Reichert, TM Morgan, G Li, E Castellanos, T Snow, FG Dall’Olio, ... Annals of Oncology 34 (1), 111-120, 2023 | 102 | 2023 |
| Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings … A Necchi, M Bandini, G Calareso, D Raggi, F Pederzoli, E Farè, ... European urology 77 (5), 636-643, 2020 | 98 | 2020 |
| Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma A Necchi, R Madison, SK Pal, JS Ross, N Agarwal, G Sonpavde, M Joshi, ... European urology focus 7 (6), 1339-1346, 2021 | 92 | 2021 |
| US phase I first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors KP Papadopoulos, E Borazanci, AT Shaw, R Katayama, Y Shimizu, ... Clinical Cancer Research 26 (18), 4785-4794, 2020 | 87 | 2020 |
| Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors JK Lee, S Sivakumar, AB Schrock, R Madison, D Fabrizio, O Gjoerup, ... NPJ Precision Oncology 6 (1), 91, 2022 | 82 | 2022 |
| Responses to alectinib in ALK-rearranged papillary renal cell carcinoma SK Pal, P Bergerot, N Dizman, C Bergerot, J Adashek, R Madison, ... Eur Urol 74 (1), 124-128, 2018 | 79 | 2018 |
| Tumor fraction correlates with detection of actionable variants across> 23,000 circulating tumor DNA samples H Husain, DC Pavlick, BJ Fendler, RW Madison, B Decker, O Gjoerup, ... JCO Precision Oncology 6, e2200261, 2022 | 74 | 2022 |
| Truncated FGFR2 is a clinically actionable oncogene in multiple cancers D Zingg, J Bhin, J Yemelyanenko, SM Kas, F Rolfs, C Lutz, JK Lee, ... Nature 608 (7923), 609-617, 2022 | 63 | 2022 |
| Genomic profiling of parathyroid carcinoma reveals genomic alterations suggesting benefit from therapy H Kang, D Pettinga, AD Schubert, PW Ladenson, DW Ball, JH Chung, ... The oncologist 24 (6), 791-797, 2019 | 58 | 2019 |
| Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer M Bandini, JS Ross, D Raggi, A Gallina, M Colecchia, R Lucianò, ... JNCI: Journal of the National Cancer Institute 113 (1), 48-53, 2021 | 46 | 2021 |
| Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder A Necchi, R Madison, D Raggi, JM Jacob, G Bratslavsky, O Shapiro, ... European Urology 77 (4), 548-556, 2020 | 46 | 2020 |
| The genomics of colorectal cancer in populations with African and European ancestry PA Myer, JK Lee, RW Madison, K Pradhan, JY Newberg, CR Isasi, ... Cancer discovery 12 (5), 1282-1293, 2022 | 45 | 2022 |
| Atypical RAS Mutations in Metastatic Colorectal Cancer F Pietrantonio, R Yaeger, AB Schrock, G Randon, S Romero-Cordoba, ... JCO Precision Oncology 3, 1-11, 2019 | 44 | 2019 |
